The case for & against
Bull & Bear analysis
Bearish
Seer, Inc. (NASDAQ: SEER) is a pioneering company in the field of proteomics technology, particularly known for its advanced ProteoGraph platform that enables deep, unbiased analysis of proteomes. By focusing on both academic and biopharma sectors, Seer aims to transform biomarker discovery and diagnostics. The company operates amidst a challenging funding environment, particularly reliant on research grants, which positions it within a broader theme of innovation in life sciences and biotechnology, particularly in the context of personalized medicine.
Bull says
- ↑ProteoGraph platform sees rising academic and biopharma adoption, validated by recent high-profile publications.
- ↑Bought back 1.5M shares at $1.78; $219.5M cash supports R&D and operations.
- ↑Analysts raised earnings estimates, reflecting strong momentum and positive sentiment.
- ↑Targeting 100K-sample proteomic study could drive meaningful revenue growth.
- ↑Defended IP with favorable patent rulings, reinforcing technological moat.
- ↑Book-to-price ~1.06 hints undervaluation; volatility presents buying opportunities.
Bear says
- ↓Q1 revenue plunged 33% YoY to $2.8M as academic funding tightened.
- ↓Gross margin down to 35% from 49%, squeezing profitability.
- ↓Annual free cash flow loss projected at $40–45M, raising burn concerns.
- ↓Low-cost imitators undercut pricing, pressuring market share and margins.
- ↓High price volatility and low institutional ownership signal elevated risk.
- ↓Small market cap vs. peers limits scalability amid competitive pressures.
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 06-02-2026neutral
Transcript signals
Bull points
- We delivered a strong start to the year with $4.2 million of revenue in the first quarter, driven by increasing demand for the Portograph product suite.
- Our impact is clearly reflected in the high-quality data our customers are generating and the acceleration of publication that further validate the power of our technology.
- we're reiterating our full-year 2025 revenue guidance of 17 to 18 million, representing 24% year-over-year growth at the midpoint.
Bear points
- while we continue to see pressure on CapEx budgets and elongated sales cycles for the outright purchase of new instruments, we were pleased by the traction we saw in terms of instrument shipments in the first quarter.
- Free cash flow loss was approximately $12.1 million for the quarter ended March 31, 2025. We continue to expect free cash flow loss to be in the range of $40 to $45 million for the year.
- Therefore, we remain cautious due to this significant macroeconomic uncertainty but are reaffirming our revenue guidance at this time.
Read full transcript analysis ›